niacinamide has been researched along with Hyperphosphatemia in 15 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia." | 9.15 | Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011) |
| "In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia." | 5.15 | Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011) |
| " Treatment discontinuation due to adverse events was 1." | 2.84 | Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. ( Brazier, M; Brisset, S; Choukroun, G; El Esper, N; Fournier, A; Kamel, S; Lemaire-Hurtel, AS; Lenglet, A; Liabeuf, S; Mansour, J; Mary, A; Massy, ZA; Mentaverri, R, 2017) |
| " The major adverse events associated with the NAM therapy were diarrhea, flushing and nausea." | 2.82 | Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. ( El Borolossy, R; El Hakim, I; El Wakeel, LM; Sabri, N, 2016) |
| " The meta-analysis showed that the nicotinamide group had a significantly higher risk of adverse events (OR 3." | 2.58 | Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis. ( Ma, T; Zhang, P; Zhang, Y, 2018) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| "Treatment with niacinamide and acetazolamide decreased TmP/GFR and serum phosphate, which was paralleled by a decrease in serum C-terminus FGF23." | 1.35 | A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. ( Brahim, J; Collins, MT; Dumitrescu, CE; Farrow, EG; Hart, TC; Kelly, MH; Khosravi, A; Murphey, MD; Nathan, MH; White, KE, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ketteler, M | 2 |
| Wiecek, A | 1 |
| Rosenkranz, AR | 1 |
| Ose, C | 1 |
| Rekowski, J | 1 |
| Lorenz, H | 1 |
| Hellmann, B | 1 |
| Karus, M | 1 |
| Ruhmann, M | 1 |
| Ammer, R | 1 |
| Fouque, D | 1 |
| Vervloet, M | 1 |
| Zhang, Y | 1 |
| Ma, T | 1 |
| Zhang, P | 1 |
| Saurette, M | 1 |
| Alexander, RT | 1 |
| Lenglet, A | 3 |
| Fabresse, N | 1 |
| Taupin, M | 1 |
| Gomila, C | 1 |
| Liabeuf, S | 3 |
| Kamel, S | 2 |
| Alvarez, JC | 1 |
| Drueke, TB | 1 |
| Massy, ZA | 3 |
| Yeung, WG | 1 |
| Toussaint, ND | 1 |
| Badve, SV | 1 |
| Rennick, A | 1 |
| Kalakeche, R | 1 |
| Seel, L | 1 |
| Shepler, B | 1 |
| Guffroy, P | 1 |
| Fournier, A | 2 |
| Brazier, M | 2 |
| El Borolossy, R | 1 |
| El Wakeel, LM | 1 |
| El Hakim, I | 1 |
| Sabri, N | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| El Esper, N | 1 |
| Brisset, S | 1 |
| Mansour, J | 1 |
| Lemaire-Hurtel, AS | 1 |
| Mary, A | 1 |
| Mentaverri, R | 1 |
| Choukroun, G | 1 |
| Ginsberg, C | 1 |
| Ix, JH | 1 |
| Dumitrescu, CE | 1 |
| Kelly, MH | 1 |
| Khosravi, A | 1 |
| Hart, TC | 1 |
| Brahim, J | 1 |
| White, KE | 1 |
| Farrow, EG | 1 |
| Nathan, MH | 1 |
| Murphey, MD | 1 |
| Collins, MT | 1 |
| Shahbazian, H | 1 |
| Zafar Mohtashami, A | 1 |
| Ghorbani, A | 1 |
| Abbaspour, MR | 1 |
| Belladi Musavi, SS | 1 |
| Hayati, F | 1 |
| Lashkarara, GR | 1 |
| Cheng, SC | 1 |
| Young, DO | 1 |
| Huang, Y | 1 |
| Delmez, JA | 1 |
| Coyne, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis[NCT03163576] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients[NCT00316472] | Phase 1 | 40 participants | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Hyperphosphatemia
| Article | Year |
|---|---|
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
Topics: Animals; Carrier Proteins; Chelating Agents; Drug Therapy, Combination; Gastrointestinal Tract; Huma | 2018 |
Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis.
Topics: Calcium; Humans; Hyperphosphatemia; Lipids; Niacinamide; Parathyroid Hormone; Phosphorus; Randomized | 2018 |
Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
Topics: Animals; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Niacin; Niacinamide; Peritoneal Dialysi | 2013 |
Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
Topics: Humans; Hyperphosphatemia; Kidney Failure, Chronic; Niacinamide; Phosphates; Renal Dialysis; Sodium- | 2013 |
Nicotinamide and phosphate homeostasis in chronic kidney disease.
Topics: Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Homeostasis; Humans; Hyperphosphatemia; N | 2016 |
6 trials available for niacinamide and Hyperphosphatemia
| Article | Year |
|---|---|
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.
Topics: Double-Blind Method; Humans; Hyperphosphatemia; Niacinamide; Parathyroid Hormone; Phosphates; Renal | 2023 |
Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
Topics: Aged; Endotoxemia; Endotoxins; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Human | 2019 |
Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
Topics: Adolescent; Chelating Agents; Child; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Fa | 2016 |
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.
Topics: Adult; Aged; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Niacinamide; Phosphorus; Prospect | 2017 |
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Diarrhea; Double-Blind Method; Female; Humans; Hyperglycemia; Hyp | 2011 |
A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
Topics: Administration, Oral; Biomarkers; Chelating Agents; Cross-Over Studies; Double-Blind Method; Down-Re | 2008 |
4 other studies available for niacinamide and Hyperphosphatemia
| Article | Year |
|---|---|
Intestinal phosphate absorption: The paracellular pathway predominates?
Topics: Animals; Clinical Trials as Topic; Diet, Western; Electrochemistry; Enterocytes; Humans; Hyperphosph | 2019 |
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.
Topics: Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Niacinamide; Phosphates; Renal Insu | 2019 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |
A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Topics: Acetazolamide; Adult; Calcinosis; Child; Diuretics; Female; Fibroblast Growth Factor-23; Fibroblast | 2009 |